Adjuvant pembrolizumab was approved for patients with renal-cell carcinoma on the basis of improvements in disease-free survival observed in the KEYNOTE-564 trial. Data on overall survival are needed.

Research findings are summarized in a Quick Take video.

To see the full article, follow this link: https://nej.md/3TVLuKz

#oncology #cancerresearch #clinicaltrials #medicalresearch #nejm